Bayer Shares Test a Key Trendline as a Busy Legal Calendar Unfolds

Bayer shares hover below key moving average as opt-out period for $7.25B Roundup settlement expires, with Supreme Court ruling adding uncertainty.

The German pharmaceutical and crop-science group finds itself squeezed between a worsening technical chart and a cluster of legal milestones that could define the next leg of its stock trajectory. With the shares hovering just below the widely watched 200-day moving average, the market’s attention has shifted squarely to the US courtroom.

The opt-out period for a proposed $7.25 billion glyphosate settlement – covering more than 60,000 claimants – expired on Thursday. The participation rate is now the critical variable: Bayer needs close to 100% of claimants to remain in the deal to bring a measure of finality to the long-running Roundup litigation. Any shortfall would re-open the door to future lawsuits and prolong the uncertainty that has plagued the stock.

Compounding the pressure, the case was transferred from a federal court in Missouri to the Northern District of California at the start of June, landing on the desk of Judge Vince Chhabria. Investors remember him well: in 2020, he rejected an earlier attempt by Bayer to reach a global settlement. His oversight of the current accord adds a layer of unpredictability to an already tense situation.

A Supreme Court ruling on the horizon
The legal calendar contains another high-stakes event. The US Supreme Court is expected to rule before the end of June on the case Durnell, which addresses whether a company can be held liable under state law for a product that the Environmental Protection Agency has deemed safe. While the Durnell decision does not directly affect the existing settlement, it could reshape the legal foundation for any future Roundup claims. For now, it amplifies the general mood of unease.

Chart mechanics reflect the strain
The stock closed Thursday at €35.39, a whisker below the 200-day moving average of €35.76. Falling under that long-term trendline is often interpreted by traders as a signal that the near-term recovery has stalled. The 50-day and 100-day averages – at €38.43 and €40.58 respectively – lie further ahead, confirming that each recent bounce has run out of steam earlier than the previous one.

Over the past month, the shares have shed 8.13%, and the seven-day decline stands at 2.99%. Since the start of the year, Bayer has lost 6.93% of its value. The relative strength index (RSI) on a 14-day basis sits at 39, edging toward oversold territory but without generating a clear contrarian buy signal yet.

The annualised 30-day volatility is running close to 38%, an elevated reading for a DAX member. That figure underscores how jittery the market has become: fresh headlines from the courtrooms routinely leave visible marks on the intraday price action.

Operational strength eclipsed by legal fog
Bayer’s underlying business remains solid. Its three divisions – Pharmaceuticals, Consumer Health and Crop Science – are delivering on their financial targets. Yet none of that fundamental performance is getting much airtime as long as the litigation overhang persists. The company’s market capitalisation stands at roughly €33.5 billion, a modest multiple relative to its earnings power when viewed through a legal-risk filter.

The current share price of about €35.34 represents a 29% gap from the February high of €49.93, though the 12-month picture still shows a 34.64% gain. The 52-week low of €25.09 offers a reminder of how far the stock has recovered from its worst levels – but also how much ground remains exposed if the legal headwinds fail to subside.

What to watch in the weeks ahead
On the upside, the €35.76 area around the 200-day average is the immediate hurdle. A decisive close above that level would relieve some of the technical pressure. On the downside, the €33–€34 zone is the next support band that traders are watching.

The most powerful catalyst, however, remains in the courtroom. Judge Chhabria’s procedural decisions on the settlement and the Supreme Court’s ruling on Durnell will likely determine whether Bayer can finally begin to trade on its operational merits – or whether the glyphosate shadow continues to darken the chart.